Saudi Arabia Next Generation Sequencing (NGS) Market Size, Share, Forecast, & Trends Analysis by Offering (Sample Preparation (DNA Extraction, Library Preparation), Instruments) Type (SMRT, DNB) Application (Clinical, Research) End User – Forecast to 2031

The Saudi Arabia NGS Market was valued at $ 24.4 million in 2023. This market is anticipated to reach $50 million by 2031 from an estimated $ 25.5 million in 2024, at a CAGR of 10.1% during the forecast period from 2024 to 2031.

Saudi Arabia NGS Market Size & Forecast

Key factors driving the growth of this market include the rise in cancer incidence, the increasing application of NGS in cancer treatment and research, and technological advancements in NGS. Furthermore, the rising adoption of genomic data management solutions and collaborations between vendors to develop library preparation protocols are expected to create market growth opportunities.

Saudi Arabia NGS Market Growth Drivers

Rising Cancer Prevalence & Increasing Application of NGS in Cancer Treatment

Cancer is a leading cause of death and a significant barrier to improving life expectancy in Saudi Arabia. Furthermore, according to GLOBOCAN, cancer incidence in Saudi Arabia is projected to reach 39,900 cases by 2030, an increase from 28,113 cases in 2022. Similarly, cancer-related mortalities are expected to increase from 13,400 in 2022 to 42,100 in 2045. This rising prevalence is anticipated to drive the adoption of NGS in clinical settings. NGS has significantly advanced researchers' understanding of cancer biology by revealing genetic heterogeneity even among cancer types previously thought to be identical. The identification of unique molecular signatures is facilitating the development of potential cancer treatments and driving the demand for NGS in cancer research. The applications of NGS in oncology research include basic drug discovery, translational research, patient testing, and clinical trials. Specifically, NGS is used for diagnostic and prognostic studies, monitoring drug resistance, biomarker identification, therapy selection, and tumor classification.

Click here to: Get Free Sample Pages of this Report

Increasing Use of NGS in Clinical Applications

NGS technology has revolutionized genetic disease diagnostics with rapid, high-throughput, and cost-effective approaches. NGS technology can simultaneously analyze hundreds of genes, the whole exome, and even the whole genome, enabling researchers to gain a deeper understanding of the genetic heterogeneity of rare diseases. NGS has great potential to enhance cancer diagnosis and care. Using NGS technology, various genomic aberrations, such as common and rare variants, structural variations (e.g., insertions and deletions), copy-number variations, and fusion transcripts, can be screened simultaneously.

NGS has gained significance in clinical practices for oncology, reproductive health, Mendelian disorders, complex diseases, and infectious diseases. In the coming years, NGS is expected to diversify in other clinical areas, with a considerable reduction in sequencing costs. The technology is expected to show substantial penetration in applications such as liquid biopsies for the early detection and monitoring of cancer and reproductive health applications. New biomarkers and actionable mutations are being identified by researchers, which are consequently expected to increase the applications and usage of NGS technology, creating growth opportunities for the players operating in the NGS market.

Saudi Arabia NGS Market Opportunity

Increasing Application of NGS in Personalized Medicine

Precision medicine is an emerging approach to patient care that customizes treatment based on an individual's genetic makeup, considering genetic changes due to disease, lifestyle factors, and environmental influences. This approach aims to move beyond the trial-and-error method of medication by providing targeted treatments based on each patient’s unique genetic profile. Precision medicine can address variability in diagnostic capabilities and aid in developing treatment strategies tailored to specific genetic and demographic characteristics. Advancements in NGS technology are transforming how doctors diagnose and treat diseases. The field of targeted treatments, which utilizes genomic data to tailor patient-specific therapies, is rapidly advancing and has increasingly become part of mainstream clinical practice. This approach involves the molecular profiling of cells to identify targetable genetic alterations, also known as biomarkers. NGS technology enables the rapid and reliable sequencing of multiple genes simultaneously. This capability has significantly contributed to the development of precision medicine, which involves customizing treatments based on specific molecular changes associated with an individual's disease.

Saudi Arabia NGS Market Trend

Development of Portable Sequencing Technologies

The development of portable handheld sequencing devices has made sequencing more affordable, simpler, and faster without requiring large clinical laboratory settings. Real-time sequencing allows researchers and physicians to quickly access and act on sequencing data. Portable nanopore-based sequencers can sequence entire genomes for less than USD 1,000. These devices work by passing DNA molecules through a nanopore, which is a small protein embedded in a membrane. As the DNA molecule moves through the nanopore, it interacts with the adaptor, creating a change in electric current. This current change is recorded and often visualized as a graph. Real-time sequencing is increasingly being adopted for various applications, including disease characterization, contaminant detection, and plant genome analysis. For instance, King Abdulaziz University in Jeddah, Saudi Arabia, funded a research study on the genotyping of the Rh Blood Group D antigen using a portable nanopore-based sequencing device.

Saudi Arabia NGS Market Analysis: Key Findings

In 2024, the Consumables Segment to Dominate the Market

By offering, the Saudi Arabia NGS market is segmented into consumables, NGS platforms/instruments, software, and services. In 2024, the consumables segment is expected to account for the largest share of 62.6% of the Saudi Arabia NGS market. This segment is projected to reach $31.8 million by 2031 from an estimated $16.0 million in 2024, at a CAGR of 10.3% during the forecast period. Ongoing advancements in reagents, kits, and target enrichment protocols, coupled with the high adoption of sequencing in healthcare facilities, are driving the demand for consumables used in NGS. The frequent use of these consumables, coupled with a growing demand for NGS-based diagnostic tests and applications in oncology, reproductive health, and drug discovery, contribute to the significant share of this market segment.

In 2024, the Targeted Genome Sequencing Segment to Dominate the Market

By sequencing type, the Saudi Arabia NGS market is segmented into targeted genome sequencing, whole genome sequencing, whole exome sequencing, and other sequencing types. In 2024, the targeted genome sequencing segment is expected to account for the largest share of the Saudi Arabia NGS market. This segment's significant market share is attributed to the advantages of targeted genome sequencing, such as low cost, quick results, and straightforward data analysis for specific areas of interest. These benefits have led to its widespread adoption in diagnostic applications.

Targeted sequencing is useful for identifying somatic mutations in complex samples such as cancerous tumors mixed with germline DNA, hence used in investigating the genetic causes of cancer and other disorders. Thus, the rising use of targeted genome sequencing in the diagnosis is further contributing to the significant market share of this segment.

In 2024, the Research Applications Segment to Dominate the Market

By application, the Saudi Arabia NGS market is segmented into research & other applications and clinical applications. In 2024, the research & other applications segment is expected to account for the largest share of 56.9% of the Saudi Arabia NGS market. This segment is projected to reach $29.3 million by 2031 from an estimated $ 14.5 million in 2024, at a CAGR of 10.6% during the forecast period. The segment's significant market share is due to the rapid adoption of NGS among academic and research institutions, the increasing demand for personalized medicine, and heightened investments by pharmaceutical and biotechnology companies in drug discovery. Additionally, the expanding applications of NGS in oncology, agriculture, and other research areas, along with the advantages of genetic research utilizing NGS technology and the rising incidence of cancer, are contributing to the segment’s significant market share.

In 2024, the Hospitals & Diagnostic Laboratories Segment to the Market

By end user, the Saudi Arabia NGS market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research centers, and other end users. In 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the Saudi Arabia NGS market. This segment’s significant market share is due to the rising demand for NGS-based diagnostic testing, improvements in healthcare infrastructure, and increasing public-private partnerships within the healthcare sector. Growing investments from both private and public entities to expand hospital capacities are further fueling the demand for NGS assays and instruments in these settings. According to the Centre for Public Policy Research (CPPR) (India), the Saudi Arabian government has invested over USD 65 billion through its Vision 2030 initiative, which supports the restructuring, privatization, and technological advancement of healthcare facilities.

Saudi Arabia NGS Market: Key Companies

The report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios and the key growth strategies adopted by them over the past three to four years. Some of the key players operating in the Saudi Arabia NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Beijing Genomics Institute (BGI) (China), Bio-Rad Laboratories, Inc. (U.S.), and 10x Genomics, Inc. (U.S.).

Saudi Arabia NGS Industry Overview: Latest Developments from Key Industry Players

• In August 2024, Illumina, Inc. (U.S.) introduced a new oncology menu for customers using the NovaSeq X Series. This includes the launch of a high-throughput version of TruSight Oncology 500 (TSO 500 HT) and the latest iteration of the distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2).
• In June 2024, Pacific Biosciences of California Inc. (U.S.), in collaboration with the International Consortium for Long-Read Sequencing (CoLoRS), launched a free HiFi long-read variant frequency database. This initiative is designed to assist rare disease researchers by offering access to genetic variants that are not detectable with the short-read sequencing method.
• In June 2024, QIAGEN N.V. (Netherlands) launched an updated version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret). This new version improves scalability and performance, specifically designed to meet the needs of high-throughput NGS laboratories.
• In July 2023, Thermo Fisher Scientific Inc. (U.S.) launched two new next-generation sequencing-based products, the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit. Both are designed for reproductive health assays and are compatible with the Ion Torrent Genexus Integrated Sequencer.

Saudi Arabia NGS Market Research Summary

Key questions answered in saudi arabia NGS market report: